Diquas ophthalmic solution 3% (diquafosol sodium, dry eye)

General information on Japanese Diquas ophthalmic solution 3% (diquafosol sodium, dry eye)

Package details: 10 bottles * 5 ml

CURRENTLY UNAVAILABLE. NO PROSPECT OF SUPPLY AT THE MOMENT, SORRY.

Manufacturer: Santen Pharmaceutical Co., Ltd., Japan

Active ingredient: diquafosol sodium (chemical formula C18H26N4O23P4)

Medical effect: Diquas ophthalmic solution is effective for the treatment of dry eye syndrome.

Contraindications and precautions: do not use for pregnant or breastfeeding women. Do not use for patients wearing contact lenses. If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Dosage and administration of Diquas ophthalmic solution 3% from Japan (diquafosol sodium, dry eye)

Apply 1 drop at a time, 6 times a day. Before applying, thoroughly wash your hands with soap. Pull down the lower eyelid so that the dropper tip does not touch eye or eyelashes. Apply the drops and do not blink, keep your eyes closed for a while.  Then wipe off any excess liquid with a clean gauze or tissue. If you other eye drops are prescribed simultaneously with this medicine, wait more than 5 minutes before applying.

How effective is Diquas ophthalmic solution 3% from Japan (diquafosol sodium, dry eye)?

Diquas ophthalmic solution contains diquafosol sodium, a purinergic P2Y2 receptor agonist. It works by a novel mechanism that activates P2Y2 receptors on the conjunctival epithelial and goblet cell membrane and elevating intracellular calcium ion concentrations. Diquas eye drops provide the following effects:

• improve keratoconjunctival epithelial disorder,
• promote secretion of mucin and water as components of tears,
• improve the tear film conditions,
• improve corneal barrier function.

Who should use Diquas ophthalmic solution 3% from Japan?

Diquas ophthalmic solution is effective against various types of dry eye diseases, such as aqueous deficiency, short tear film breakup time, and obstructive meibomian gland dysfunction. Also, these eye drops help to treat dry eye disease resulting from surgery (for example, in situ keratomileusis and cataracts) and from the use of contact lenses and visual display terminals (Jin  Hyoung Park, Seong-Ho Moon et al. “Diquafosol Sodium Inhibits Apoptosis and Inflammation of Corneal Epithelial Cells Via Activation of Erk1/2 and RSK: In Vitro and In Vivo Dry Eye Model”. Investigative Ophthalmology & Visual Science, 2018, October, Vol. 59, 5108-5115). The effectiveness is maintained up to 12 months after the course of the treatment.